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ABSTRACT 
The Epidermal Growth Factor Receptor (EGFR/ErbB) receptor tyrosine kinase 
(RTK) family has been implicated in numerous cancer types (e.g. lung, breast and brain) 
and this signaling network is conserved from Drosophila to humans.  For this reason, 
Drosophila may provide an ideal in vivo system for experimental analyses of this 
pathway and a chemical genetics approach to the identification of therapeutics against it. 
Towards this goal, an assay utilizing Drosophila transgenic for members of the human 
ErbB family was developed for screening putative inhibitory compounds.  Preliminary 
phenotypic data with known EGFR inhibitors yielded promising results. 
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BACKGROUND 
Cancer is a worldwide problem, affecting millions of people from every age, 
gender, race, and nationality and accounting for over ten percent of the total deaths in the 
world each year (World Health Organization, 2006).  Cancer has been identified in most 
body organs and new forms continue to be characterized.  In hopes of finding potential 
treatments, or a cure, human cancer has become widely studied and more becomes 
known about the disease daily.  As more is understood about its causes, researchers are 
able to begin to develop treatments that specifically target pathways (e.g. ErbB) in which 
dysregulation leads to oncogenesis.  
The ErbB family of Receptor Tyrosine Kinases 
Protein kinases are essential to the human body because they are involved in 
regulating many biological functions through signaling pathways (Olayioye, 2001).  
There are nearly 60 different human receptor tyrosine kinases (RTKs) encoded by the 
human genome (Figure 1), which can be broken into 20 sub-families (Blume-Jensen and 
Hunter, 2001).  These receptors each have different structures and roles in the body, but 
all are made up of an intracellular domain containing the kinase domain, a 
transmembrane domain, and an extracellular domain (Blume-Jensen and Hunter, 2001).  
Additionally, tyrosine kinase receptors are involved in many different cell signaling 
pathways that relay information to the nucleus (Schlessinger and Lemon, 2006).  These 
intracellular pathways are responsible for regulating many cell functions such as 
proliferation, differentiation, migration, and apoptosis. 
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Among the RTKs, the ErbB family is one of the better studied families of 
receptors.  The ErbB family consists of 4 different receptors: Epidermal Growth Factor 
Receptor (EGFR/EGFR), ErbB2, ErbB3, and ErbB4 (Linggi and Carpenter, 2006, 
Bogdan and Klämbt, 2001).  Like other RTKs, the ErbB receptors contain an 
extracellular ligand-binding region, a small transmembrane region, and an intracellular 
tyrosine kinase region surrounded by a juxtamembrane region and a carboxyl (C-) 
terminal tail (Burgess et al., 2003).  The ErbB receptors have four extracellular 
subdomains, I – IV, with regions II and IV being cysteine-rich and regions I and III being 
important for ligand-binding. (Burgess et al., 2003; Linggi and Carpenter, 2006; Stein 
and Staros, 2000). 
The current model proposes two forms for the ErbB receptor monomers relating 
to their activation.  When in its inactive form, ErbB receptors are tethered monomers, 
with the extracellular region folded over on itself (Linggi and Carpenter, 2006).  ErbB 
 
Figure 1: Human protein tyrosine kinase receptor families.  All together, there are 58 different human 
RTKs split into 20 different families.  This figure illustrates the many variations among the different RTKs.  
(Taken from: Blume-Jensen and Hunter, 2001) 
7 
receptors are activated through the binding of a ligand, such as EGF, to the receptor and 
the subsequent dimerization of the receptor as shown in Figure 2 (Burgess et al., 2003; 
Linggi and Carpenter, 2006).    The model suggests that ligand binding causes the 
dimerization arms of the ErbB receptors to become exposed, allowing two receptors to 
dimerize (Lemmon et al.,1997; Burgess et al., 2003).  Dimerization activates the kinase 
activity of the receptors which in turn causes the monomers to transphosphorylate 
tyrosine residues in their C-tail (Linggi and Carpenter, 2006).  This intermolecular 
phosphorylation of C-tail tyrosines triggers signaling pathways in the cell.  The nature of 
the pathway triggered depends on many factors, such as the ligand bound and the 
dimerized receptors (Yarden and Sliwkowski, 2001). 
 
Each ErbB receptor is thought to have a slightly different role in the body, and 
have different ligand specificities but only EGFR and ErbB4 are fully functional, 
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Figure 2: Activation of the ErbB receptor.  In its inactive form, EGFR typically has a tethered, 
folded-over structure, but when EGF ligand binds, the EGFR opens and is able to dimerize with itself 
or another ErbB receptor.  This dimerization activates the receptor and triggers autophosphorylation of 
the C-tail tyrosine residues. 
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containing both ligand binding and kinase activity (Burgess et al., 2003). The ErbB2 
receptor lacks ligand binding activity, rendering it inoperative unless it dimerizes with 
another ErbB family member, capable of binding to ligand (Burgess et al., 2003; Linggi 
and Carpenter, 2006).  ErbB3, on the other hand, has a working extracellular receptor 
region, but an inactive tyrosine kinase domain, so it is unable to phosphorylate C-tail 
tyrosines, but can act as a substrate for the kinase domain of another receptor if a 
heterodimer is formed (Burgess et al., 2003).  Although ErbB2 and ErbB3 alone lack full 
receptor binding and kinase functions, the ErbB2-ErbB3 heterodimer is the most 
mitogenic and transforming RTK complex (Yarden and Sliwkowski, 2001).  
Additionally, it has been suggested that EGFR is capable of bypassing canonical 
signaling cascades and translocating to the nucleus where it can more directly regulate 
gene expression and cellular processes (Lo and Hung, 2006). 
ErbB Receptor Signaling Pathways and Cancer 
The ErbB family has been implicated in many types of human cancer and, as a 
result, is one of the most studied signaling networks.  Commonly, cancer occurs when the 
ErbB pathway becomes hyper-activated by the overproduction of ligands, overproduction 
of ErbB receptors, or constitutive activation of ErbB receptors (Yarden and Sliwkowski, 
2001).  Many experiments have shown that ErbB RTKs lead to development of cancer, 
particularly through misregulation of the phosphatidylinositol-3 kinase (PI3K) and 
mitogen-activated protein kinase (MAPK) signaling pathways (Holbro et al., 2003; 
Yarden and Sliwkowski, 2001).  This misregulation often occurs as a result of mutations 
in the ErbB family, which leads to overexpression or constitutive activation of the 
receptor signaling pathways (Holbro et al., 2003; Yarden and Sliwkowski, 2001).   
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In an ordinary cell, the autophosphorylation of ErbB receptors triggers the 
activation of intracellular pathways necessary for normal development (Yarden and 
Sliwkowski, 2001).  Mouse models have shown that ErbB receptors are vital to normal 
development and survival.  As reviewed by Hynes and Lane, mice embryos without 
ErbB2, which is required for development of the heart, die due to improper chamber 
formation and blood flow in the heart, while mice without EGFR die soon after birth, due 
to respiratory problems as well as skin and gastrointestinal problems (2005). 
The activation of different intracellular signaling pathways as a result of ErbB 
RTK activation and autophosphorylation is based principally on the adaptor molecules 
that bind to the phosphorylated tyrosines in the ErbB receptor C-tail (Batzer et al., 1994).  
As shown in Figure 3, both the PI3K and MAPK signaling cascades triggered by the 
ErbB receptors lead to a nuclear cell signal.  Phosphophotyrosine binding proteins with 
SH2 or PTB domains commonly act as adaptors between the activated ErbB receptor and 
RTK signaling pathway (Batzer et al., 1994; Luschnig et al., 2000).  Two adaptor 
proteins, Grb2 and Shc, provide a common link between the EGFR receptor and two 
main signaling cascades: MAPK and PI3K (Batzer et al., 1994; Luschnig et al., 2000).  It 
is suggested that Grb2 and Shc form a complex, together binding to specific 
phosphotyrosine residues on EGFR and then linking to SOS, thereby triggering the 
MAPK pathway.  PI-3K binds directly to phosphorylated tyrosines in ErbB3 and ErbB4 
via SH2 domains on its p85 subunit, but binds indirectly to EGFR through a Shc adaptor 
molecule, GAB1, that binds via Grb2 (Hynes and Lane, 2005; Blume-Jensen and Hunter, 
2001). 
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Receptor Tyrosine Kinase (RTK) Inhibitors 
As was previously discussed, RTKs function in regulating the proliferation, 
differentiation, migration, metabolism, and survival of the cell (Calbiochem, 2006).  
Since it is known that hyperactivation of these kinases in many cases leads to cancer, the 
use of RTK inhibitors is becoming of more interest as a novel cancer treatment.  Receptor 
tyrosine kinase inhibitors are promising cancer therapeutics because of their ability to 
block the kinase activity of the receptor, inactivating the pathway.  Many ErbB tyrosine 
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Figure 3: Oncogenic signaling pathways activated by the activation of ErbB receptors.   Binding of ligand to 
the receptor is responsible for the cross phosphorylation of the receptor dimer and subsequent pathway activation.  
Conserved phosphotyrosine sequences bind to the SH2 domains of signaling molecules which activate the 
PI3K/AKT (left) and MAPK (right) pathways which have been implicated in many cancers. 
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kinase inhibitors (TKIs) work by binding somewhere at the ATP pocket, which blocks 
ATP from binding to the kinase domain of the receptor (Baselga, 2002; Janmaat and 
Giaccone, 2003).  The binding of these small molecule TKIs prevents signal transduction 
from the ErbB receptor by blocking ATP binding and kinase activity; thereby preventing 
autophosphorylation of the receptor (Baselga, 2002; Janmaat and Giaccone, 2003).   
Development of Receptor Tyrosine Kinase Inhibitors 
As more has become known about the molecular basis of cancer, molecularly 
targeted compounds, such as TKIs, have been developed as new cancer therapies.  With 
the growing knowledge base, it is hoped that the design of cancer drugs will become less 
costly, and more effective (Benson et al., 2006).  With so many different molecular 
compounds available, and so few proving worthwhile as cancer therapeutics, it is 
important to “validate” potential cancer target drugs before investing extensive time and 
funding into their development (Benson et al., 2006).  As a cost and time saving measure, 
it has now become common to screen chemical and molecular libraries for promising 
compounds prior to any clinical trials to “validate” them as potential drugs.  Recombinant 
catalytic-kinase domains are often used to screen for protein kinase inhibitors, and as a 
result, many TKIs work by competing with ATP (Sebolt-Leopold and English, 2006).  
This drug screening process is important because it is allows scientists to initially reject 
compounds that would likely produce only weak effects. 
Quinazolines 
Hundreds of additional TKIs have been discovered or synthesized.  Of the many 
known TKIs, one class of inhibitors, the quinazolines, appears to be the most promising 
clinically for EGFR inhibition (Baselga, 2002).  These compounds covalently bind to the 
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ATP pocket of the kinase domain of the ErbB receptors, competing with ATP binding 
and inhibiting the activation of the kinase domain (Discafani et al., 1999; Fry et al., 
1998).  As a result, they have to potential to block the EGFR pathway by inhibiting the 
autophosphorylation that triggers the oncogenic pathway.  Two of these chemical 
inhibitors, CL-387,785 and PD 168393, have been shown to block activation of the 
EGFR pathway and are further examined as experimental cancer therapeutics in this 
project.  
N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785) is an 
irreversible tyrosine kinase inhibitor.  CL-387,785 is a quinazoline compound with 
chemical formula C18H13BrN4O, comprised of a benzene ring fused with a pyrimidine as 
shown in Figure 4.  It was developed after molecular modeling of the EGFR kinase 
domain, and looks promising as a clinical EGFR inhibitor for cancer treatment (Discafani 
et al., 1999).  CL-387,785 competes with ATP binding of the receptor, which is able to 
significantly decrease, or inhibit altogether, the kinase domain’s autophosphorylation of 
the receptor tail (Discafani et al., 1999).  It appears to work by alkylating Cys
773
 and 
covalently binding with the EGFR (Discafani et al., 1999).  Initial experiments showed 
that CL-387,785 blocked EGFR autophosphorylation and inhibited tumor growth both in 
vitro and in vivo (Discafani et al., 1999).  
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Additionally, 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline (PD 168393) 
is an irreversible EGFR tyrosine kinase inhibitor (Fry et al., 1998).  A small, quinazoline 
molecule with chemical formula C17H13BrN4O (Figure 5), PD 169393 is a strong 
inhibitor of the EGFR.  The compound works by alkylating Cys
773
 which inhibits ATP 
binding and prevents activation of the EGFR kinase domain (Fry et al., 1998).  With an 
inactive kinase domain, EGFR is unable to autophosphorylate tyrosines in its tail, and the 
pathway is not activated.  Experimental in vivo data, as discussed by Fry et al., showed 
that PD 168393 was a strong inhibitor of EGFR and was much more potent than other 
known inhibitors (Fry et al., 1998). 
Clinical Data 
Based on some initial molecule screenings, several tyrosine kinase inhibitors have 
shown positive inhibition results and are already undergoing preclinical or clinical trials 
 
Figure 4: Chemical Structure of CL-387,785 highlighting the binding site with EGFR.  Picture adapted 
from the EMD/Calbiochem website,  http://www.emdbiosciences.com/product/233100 
 
Figure 5: Chemical Structure of PD 168393 highlighting the binding site with EGFR. Picture adapted from 
the EMD/Calbiochem website, http://www.emdbiosciences.com/product/513033 
Alkylation Site 
Alkylation Site 
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as treatments for cancer (Baselga, 2002; Janmaat and Giaccone, 2003).  Each TKI is 
slightly different, regarding its binding specificity and reversibility as an inhibitor, but 
several look promising as treatments once further research and clinical trials occur.   
Additionally, several tyrosine kinase inhibitors targeting different members of the 
ErbB receptor have already been approved for use in the treatment of several types of 
cancers (Hynes and Lane, 2005).  Two current human clinical TKIs for EGFR, Gefitinib 
and Erlotinib, are approved as a therapy for non-small cell lung cancer (NSCLC) once the 
primary and secondary treatments have proven unsuccessful (Hynes and Lane, 2005; 
Janmaat and Giaccone, 2003).  Furthermore, these therapeutics might prove to be 
effective for more than NSCLC.  Gefitinib, for example, is being evaluated as a therapy 
for head and neck squamous-cell carcinoma, gastrointestinal cancer, and breast cancer 
and Erlotinib is undergoing trials for the treatment of additional types of cancer as well 
(Hynes and Lane, 2005).   
Drosophila as a Model 
The utility of Drosophila melanogaster, commonly known as the fruit fly, as a 
system to model human disease and test potential treatments is rapidly increasing.  Since 
the sequencing of both the human and Drosophila genome, it has been shown that a 
majority of human disease genes have been conserved in Drosophila (Fortini et al., 
2000).  With the finding that 62% of the human disease genes are conserved, researchers 
have been turning more and more to Drosophila to model genetic diseases (Rubin et al., 
2000). 
Additionally, 68% of the human cancer genes appear to have a homologous 
sequence in Drosophila, including the ErbB family of genes which correlate with the 
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Drosophila EGFR gene, dEGFR (Rubin et al., 2000).  Although they are relatively small 
organisms, Drosophila contain many highly organized signaling pathways regulated by 
numerous intracellular and extracellular molecular signals, e.g. the MAPK pathway (Li 
and Garza, 2003).  Drosophila are currently used for genetic screening, and it seems that 
with little effort flies could be used to screen compounds as well.  While cellular assays 
are often used, they are less than ideal since they are often based solely on target 
interaction and can be limiting as a chemical genetics screen (Li and Garza, 2003).  The 
drug effects can be studied in a living organism in more detail than is possible with a 
cultured system, paying attention to toxicity and off-target effects (Manev et al., 2003).   
Additionally, the use of GAL4-UAS system in Drosophila allows for targeted 
expression of a gene of interest (Duffy, 2002).  The crossing of the responder (UAS) and 
driver (GAL4) enables the overexpression of a gene and the corresponding phenotype 
(e.g. lethality) can be studied (Duffy, 2002; Li and Garza, 2003).  Taking it one step 
further, compounds that inhibit these phenotypes could be identified by using a chemical 
genetics assay by observing phenotypic reversion (Li and Garza, 2003).  
 For such studies, Drosophila oogenesis provides an experimental system well 
suited for such chemical genetics studies.  Previous studies have shown that Drosophila 
females can be fed small molecules and effects can be noted on developing egg 
chambers.  For example, feeding females colchicine led to the disruption of microtubule 
structure and pattern in developing egg chambers (Townsley and Bienz, 2000).  As more 
studies have shown the ability to feed Drosophila chemicals and observe phenotypic 
results, flies have been identified as a potential model for pharmacological research.  
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Additionally, methods of administering drugs via feeding, injection, or inhalation of 
desired chemicals, show the practicality of the Drosophila model (Manev et al., 2003).   
 In Drosophila dEGFR activity within the follicle cells determines the dorsal fates, 
and dorsal ventral polarity of the eggshell (chorion) provides a very simple marker for 
dEGFR activity.  Specification of dorsal appendages allows the different levels of 
dEGFR activation to be identified, allowing for easy phenotypic characterization of 
activity.  Wildtype flies lay chorions with 2 dorsal appendages, while flies lacking EGFR 
activity lay ventralized chorions. In contrast, flies with hyperactive EGFR signaling lay 
dorsalized chorions, easily observed by the presence of ectopic dorsal appendages. 
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STATEMENT OF PURPOSE 
Many experiments have confirmed the relationship between misregulation of the 
ErbB receptors and the development of certain types of cancer.  While ErbB receptors are 
necessary for normal development, the hyperactivation of these receptors and subsequent 
autophosphorylation of their kinase domains leads to the constitutive activation of 
downstream signaling proteins, thereby contributing to cancer.  To date, the most 
common cancer treatment is chemotherapy, with additional molecular drugs used as a 
second or third option when initial treatments do not seem effective.  Still, much time and 
money are being put into developing targeted cancer therapeutics with the hope of 
increased efficacy and reduced toxicity. 
With the conservation of the receptor and intracellular signaling pathways 
between Drosophila and humans, it seems practical that fruit flies could be used to screen 
for cancer therapeutics.  Additionally, with the ability to make flies transgenic for the 
human ErbB gene, it is possible to use Drosophila for chemical genetic screens to 
identify cancer drugs targeted specifically to the human ErbB family members.  Instead 
of relying on a high throughput cell culture screen, an assay using Drosophila would 
enable the inhibitor effects to be studied in a complete organism instead of a cell line. 
The goal of this project was to determine if Drosophila could be used to identify 
novel therapeutics for EGFR dependent cancers.  Additionally, development of a high 
throughput chemical genetics assay using Drosophila oogenesis was desired to screen 
chemical libraries to identify inhibitors of RTKs implicated in human disease. 
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MATERIALS AND METHODS 
Bioinformatics 
Using the full length sequences for the human EGFR, ErbB2, ErbB3, and ErbB4 
proteins as well as the Drosophila dEGFR protein, a ClustalW 1.8 sequence alignment 
(http://searchlauncher.bcm.tmc.edu/multi-align/multi-align.html) of the intracellular 
regions for each protein RTK was performed.  The resulting alignment was imported into 
the Curation and Alignment Tool for Protein Analysis (CATPA) program 
(http://www.catpa.org).  Using CATPA, sequences were then annotated with respect to 
tyrosine residues, kinase domains, and sequences surrounding C-tail tyrosines that were 
conserved between the human and fly receptors. 
Using the online UniProt Knowledgebase (http://ca.expasy.org), the kinase 
domain for each receptor of was identified and annotated in CATPA.  To confirm the 
alignment and CATPA analysis, each protein was also individually screened by eye for 
tyrosine residues after the kinase domain.  The sequences surrounding each tyrosine  
were compared to determine which tyrosines were conserved between the ErbB family 
and dEGFR.  Once the conserved sequences surrounding the tyrosines were determined, 
it could be predicted what adaptor molecules would likely bind to the phosphorylated 
tyrosine residues. 
Additionally, the complete sequences of other human RTKs were obtained online 
from both the Uniprot Knowledgebase and NCBI Entrez Protein database 
(www.ncbi.nlm.nih.gov/Entrez/).  Using the two conserved tyrosine consensus sequences 
(sxLqRYsxDPt, VxNPEYL) obtained from the ErbB family analysis, the RTK family 
members were screened for similarities in intracellular tyrosine residues.  
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Drosophila Genetics 
Virgin female flies from stocks [UAS-EGFR·GFP]
KC7a 
/ TM3,Sb, [UAS-
dEGFR1·GFP]
1E III
 , [UAS-EGFR·GFP]
KC7b
 / CyO, [UAS-EGFR]
22 II
, [UAS-ErbB3]
24-2
 / 
TM3,Sb and [UAS-ErbB3]
66
 / CyO were collected and crossed with males for different 
drivers ([CY2-GAL4], [Act-GAL4][tub-GAL80
ts
]
R2
 / CyO, [CY2-GAL4][tub-GAL80
ts
]
R9
 / 
CyO, [GMR-GAL4][UAS-EGFR·GFP]
KC7b
 / CyO).  These flies were allowed to mate in a 
vial with yeast for a few days and flipped into new vial or bottle to continue mating and 
produce many progeny.  The F1 generation was sorted by phenotype to select for the 
correct genotype, and female flies of the correct genotype were used for drug testing and 
egg lays, as well as anti-EGFR, anti-dEGFR staining, and GFP staining.  Wild-type, 
W
1118
, flies were also maintained and used for experimental controls.  
Unless otherwise noted, all flies were kept on standard media at room 
temperature.  Crosses with the temperature sensitive strains, [Act-GAL4][tub-GAL80
ts
]
R2
 
/ CyO, and [CY2-GAL4][tub-GAL80
ts
]
R9
 / CyO, were kept at 28.5°C to deactivate 
GAL80. 
Apple juice Agar 
Typical agar recipes were modified to include apple juice and additional sugar to 
attract fruit flies.  For one liter of agar, 22 grams of agar was dissolved in 500 mL of 
distilled water in the microwave until in solution.  Half a can of frozen apple juice was 
heated and mixed with 32 grams of sucrose and enough dH20 to make 500 mL of 
solution.  When both solutions were dissolved, they were combined, and poured into 
individual or multi-well plates.  Remaining apple juice agar was covered and stored at 
4˚C.  
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Chorion Preps 
Chorions from the various Drosophila F1 genotypes were obtained using egg lay bottles.  
8-10 female flies from each genotype of interest and 2-3 male flies were placed in empty 
bottles with small holes to allow in oxygen.  Plates made with apple juice agar were 
dotted with a yeast paste and put on the bottle tops.  The plate was taped on to keep the 
flies inside, and the bottles were turned upside down and left overnight at 25°C.  The 
following day, the original plates were replaced with new apple juice plates, and the 
chorions were observed and collected from the plates (Figure 6).  Chorions were placed 
on a slide in Lacto-Hoyer’s (50-50) solution, and placed overnight on a 65°C hotplate.  
The chorions were viewed using dark field microscopy at 100x magnification and images 
were taken. 
Histochemistry 
Between 6 and 8 flies per genotype were knocked out with CO2 and their ovaries 
were removed and dissected in PBT (0.1% Tween20 in 1xPBS) in a glass dish.  The 
dissected ovaries were fixed in 3.7% formaldehyde in PEMP (10 mL 0.5M PIPES, 
100µL 1M MgSO4, 100 µL 0.5M EDTA, 50µL NP-40, 39.75 mL dH20) for 15 minutes.  
 
Figure 6: Example of Drosophila egg lay procedure.   Flies were placed overnight into upside-down bottles 
with apple juice agar plates at the bottom, as shown on the left.  The following day, the apple juice plates 
were removed and the chorions inspected under a dissection microscope.  The egg lay plate with chorions is 
shown in the center image and an example of wild-type chorions viewed under the microscope is shown on 
the right. 
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The ovaries were rinsed 3 times in the glass dish with Ab wash (20 mL 1M TrisCl pH 
7.4, 6mL 5M NaCl, 200 µL NP-40, 200 mg BSA, 174 mL dH20) before being transferred 
to a 0.5 mL Eppendorf tube for 2 additional rinses.  The ovaries were blocked with Ab 
block (5% BSA (5mg/mL) in Ab wash) for 1 hr at room temperature.  The block was 
removed, and rotated overnight at 4˚C in 50 µL 1˚ antibody (1:1000 dilution in Ab wash 
for mouse anti-EGFR Ab-12 cocktail (Neo Markers) and rabbit anti-dEGFR(Duffy Lab)).  
The 1˚ antibody was removed, and the ovaries were washed 8-10 times in Ab wash for 5 
minutes each time.  The 2˚ antibody (Alexa Fluor 488, specific to the 1˚) was diluted 
1:400 in Ab wash and rotated for 2 hours at room temperature.  Remove 2˚ antibody and 
wash 8-10 times in Ab wash for 5 minutes each before mounting in 70% glycerol.  Once 
mounted on slides, the ovaries were observed using fluorescent microscopy to observe 
EGFR and dEGFR expression and localization. 
Between 6 and 8 flies per genotype were knocked out with CO2 and their ovaries 
were removed and dissected in PBT in a glass dish.  The dissected ovaries were fixed in 
3.7% formaldehyde in PBT for 15 minutes.  The ovaries were rinsed 3 times in the glass 
dish with before being transferred to a 1.5 mL Eppendorf tube for 2 additional rinses.  
The ovaries were then mounted in 70% glycerol, mounted on slides, and observed using 
fluorescent microscopy to observe GFP production and localization in the cells.  
Inhibitor Treatments 
CL-387,785 (catalog # 233100) and PD 168393 (catalog # 513033) were ordered 
from Calbiochem.  The stock vials of each TKI were taken up in 200ul DMSO for a 
concentration of approximately 13mM for each.  For the Drosophila drug treatments, 
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some stock CL-387,785 (CL) and PD 168393 (PD) were diluted in a dilute apple juice 
dH20 mixture to obtain various concentrations (1:100 – 1:500) for the drug treatments.  
The Drosophila F1 generation expressing the CY2-GAL4 driver were used for 
inhibitor screening.  For the project, it is important to maximize and optimize the drug 
screening capability, while maintaining sufficient phenotypic data to analyze the drug 
effects so different sized multi-well plates, different numbers of flies, and different drug 
concentrations were used to determine the optimal testing conditions.  Table 1 shows the 
various experimental conditions tested for the assay. 
Trial 
# 
Flies per well 
(in 48 well plate) 
Inhibitor & 
Concentration 
Other variables 
1 3 females 10 µL CL (1:500) RT, flies >3 days old 
2 3 females 10 µL CL (1:500) 
Flies ~2 days old, room temp 
~21°C 
3 3 females 10 µL CL (1:500) 
Temp in room varied, flies ~2 
days old 
4 
3 females + 1 WT 
male 
10 µL CL (1:500) 
Flies starved ~ 6 hrs before, ~2 
days old, RT 
5 
3 females + 1 WT 
male 
10 µL CL (1:100) or 
10 µL PD (1:100) 
Dark agar, starved flies, room 
temp varied, removed wings, ~2 
days old 
6 
3 females + 1 WT 
male 
10 µL CL (1:100) or 
10 µL CL (1:500) or 
10 µL CL (1:1000) 
25°C incubator, starved, 
removed wings, ~2days old 
Table 1: Experimental Conditions for Chemical Genetics Assay. 
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RESULTS 
Identification of Conserved Adaptor Binding Sites 
A Curation and Alignment Tool for Protein Analysis (CATPA) data file was 
created for the ErbB and dEGFR protein (Figure 7).  Within the alignment file, the kinase 
domains and conserved tyrosine residues were highlighted to show conserved sequence 
homologies.  Additionally the program allowed comments to be added about the 
residue/domain of interest so experimental data could be tied with the sequence data in 
the same file. 
Figure 7: Screenshot of the CATPA Program.  Features of the program are highlighted such as the comment feature 
and ability to mark off residues and/or domains.  In addition to a color scheme showing conserved and similar 
residues, the individual conserved tyrosine sequences were marked off and labeled for easy visualization.  By clicking 
on a labeled residue, the user is able to pull up useful information such as images from outside experimental data, 
creating a data file with useful information about the proteins of interest. 
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The goal of the sequence analyses of EGFR, ErbB2, ErbB3, ErbB4 and dEGFR 
was to identify conserved tyrosine residues.  Since the tyrosines (Y) in the kinase domain 
are not essential for activation of intracellular pathways, focus was placed only on 
conservation of the C-tail Y residues (Table 2).  Since phosphorylated tyrosines in 
dEGFR activate the fly MAPK pathway, it was expected that the human ErbB receptors 
would only activate the pathway if it contained residues that were conserved with 
dEGFR. 
 EGFR ErbB2 ErbB3 ErbB4 dEGFR 
Tyrosines in 
tail 
9 9 14 19 14 
Tyrosines 
Conserved 
2 2 0 1 2 
Table 2:  C-tail tyrosine analysis data for ErbB and dEGFR. 
 
Two tyrosine sequence homologies between the human and Drosophila receptor 
tail were identified (Table 3).  The two consensus sequences were identified, 
sxLqRYsxDPT and VxNPEYL.  The first, sxLqRYsxDPT, is conserved within EGFR, 
ErbB2, ErbB4, and dEGFR, while the second, VxNPEYL, is conserved in EGFR, ErbB2, 
and dEGFR.    
Consensus SPxDSxFYRxL vDAeEYLvPQqgFf sxLqRYsxDPt PeYhN VxNPEYL tAENpEYL 
       
EGFR 
SPTDSNFYRAL 
(Y-998) 
VDADEYLIPQQGFF 
(Y-1016) 
SFLQRYSSDPT 
(Y-1069) 
PVYHN 
(Y-1110) 
VGNPEYL 
(Y-1138) 
TAENAEYL 
(Y-1197) 
ErbB2 
SPLDSTFYRSL 
(Y-1005) 
VDAEEYLVPQQGFF 
(Y-1023) 
SPLQRYSEDPT 
(Y-1112) 
PEYVN 
(Y-1139) 
VENPEYL 
(Y-1196) 
TAENPEYL 
(Y-1248) 
ErbB3 
 
 
     
ErbB4  
MDAEEYLVPQAFN 
(Y-1021) 
SSTQRYSADPT 
(Y-1128) 
PEYHN 
(Y-1188) 
 
VAENPEYL 
(Y-1284) 
dEGFR   
PKLNRYCKDPS 
(Y-1271) 
 
VDNPEYL 
(Y-1357) 
 
Table 3: Consensus tyrosine sequences between the ErbB family and dEGFR.   For each receptor, residues surrounding the 
tyrosine residues in the C-tail were compared to determine sequence similarities and a consensus sequence for the receptor 
family.  Capital letters in the consensus sequence indicate residues conserved in all receptors, lowercase letters indicate 
conservation in most, and x indicates a lack of consensus for that residue. The number of each receptor’s tyrosine residue for 
each consensus sequence is listed in parentheses.  
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Furthermore, it was determined to which signaling pathway molecules the 
conserved tyrosines might bind, focusing only on the two sequences that were conserved 
between ErbB and dEGFR (Figure 8).  By focusing on the conserved sequence and 
tyrosine residue number for each receptor, adaptor molecule(s) that are predicted to 
interact with the ErbB/dEGFR conserved phosphotyrosine residues were identified.  The 
consensus sequences VxNPEYL, found surrounding EGFR (Y-1138), ErbB2 (Y-1196), 
and dEGFR (Y-1357), is predicted to bind to a Shc-Grb2 complex through the interaction 
of the Shc PTB domain with the receptor phosphotyrosine residue (Batzer et al., 1995; 
Olayioye, 2001; Schultze et al., 2005).  The binding of this complex to the activated 
receptor triggers the MAPK pathway (Seet et al., 2006).  Additionally, the consensus 
sequence sxLqRYsxDPT, shown to be conserved between EGFR (Y-1069), ErbB2 (Y-
1112), ErbB4 (Y-1128), and dEGFR (Y-1271) is predicted to bind to the SH2 domain of 
Grb2 (Batzer et al., 1994; Olayioye, 2001; Schultze et al., 2005).  Grb2 binding, as 
previously discussed, is responsible for activating the MAPK pathway (Seet et al., 2006). 
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After the analysis of the ErbB receptor family, it was decided to screen selective 
members of the remaining RTK families to determine if any experimental data could be 
applied beyond the ErbB RTKs.  Receptor sequences were obtained and screened for the 
dEGFR and ErbB consensus residues, sxLqRYsxDPT and VxNPEYL.  Analysis of those 
sequences showed 7 out of 18 receptors with at least partial conservation (Table 4) of the 
residues in the ErbB and dEGFR consensus. 
 
sxLqRYsxDPt
VxNPEYL
Shc & Grb2 binding
Grb2 binding
EGFR/ErbB1 ErbB2 ErbB3
dEGFR
ErbB4
PY-1069
PY-1138
PY-1112
PY-1196
PY-1128
PY-1357
PY-1271
  
 
Figure 8: The tyrosine residues on the ErbB and dEGFR tails.  The first set of conserved sequences, shown 
in purple, appears responsible for the binding to a SH2 domain, such as is found in Grb2 protein.  The second 
set, shown in green, appears responsible for the binding of a PTB domain, such as is found in Shc.  The colored, 
boxed regions on the tail show conserved tyrosine residues and their location in the receptor sequence.  The 
related consensus sequences and the potential molecules that bind to the phosphorylated tyrosines are shown on 
the left side of the figure.  The dashes in the tail show the tyrosine residues that were not conserved. 
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Functional Analysis of Human EGFR in Drosophila 
Our bioinformatics analysis predicts that EGFR, ErbB2, and ErbB4, but not 
ErbB3 might be capable of activating the Drosophila MAPK pathway through 
association with adaptor proteins.  To test this, EGFR and ErbB3 were misexpressed in 
transgenic Drosophila during oogenesis and eye development. 
EGFR, ErbB3, EGFR·GFP, and dEGFR·GFP were misexpressed in the ovaries 
and eyes.  The phenotypes were evaluated to determine which lines should be used for 
the development of the chemical genetics assay.  Phenotypic differences were easiest to 
detect with CY2-GAL4 misexpression so they were pursued for use in the development 
of the assay.  The wildtype, EGFR and ErbB3 chorions appeared normal, while the 
chorions from EGFR·GFP and dEGFR·GFP genotypes showed dorsalization effects, 
demonstrating that these transgenes were capable of hyperactivating the EGFR pathway 
(Figure 9). 
Receptor Name Accession number Conserved Y residues 
PDGFRb NP_002600  
INSR AAA59452 NPEYL (Y-999) 
VEGFR NP_002010 PEY (Y-1124) 
FGFR1 AAH15035 NqEYL (Y-764) 
TRKA BAA34355 PvYL (Y-791) 
EPHA1 P21709  
EPHB2 P29323  
AXL NP_068713 EYL (Y-662) 
TIE NP_005415  
TEK Q02763 (UniProt)  
RYK NP_001005861  
DDR1 AAH70070  
RET AAH03072  
ROS P08922(UnitProt)  
LTK AAH45607  
ALK NP_004295 PEYkL (Y-1078) 
ROR1 Q01973 (UniProt) EYL (Y-605) 
MUSK AAI09100  
Table 4: Potential Adaptor Binding Sites in other RTKs.  Using the tyrosine residues conserved between 
dEGFR and ErbB (Table 3), other RTK family members were screened for the consensus sequence to determine 
if they were capable of activating the same pathways. 
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It was surprising that effects were only seen with EGFR·GFP and not EGFR 
although both contain the same conserved adaptor binding sites.  Thus, to determine if the 
absence of effects with untagged EGFR was due to lack of expression or aberrant 
localization, EGFR·GFP
KC7a
, EGFR·GFP
KC7b
, EGFR, dEGFR·GFP, and wildtype ovaries 
were stained with an antibody towards either dEGFR or EGFR (Figure 10) and for GFP 
tagged molecules GFP expression was also assessed (Figure 11).  The antibody staining 
for EGFR·GFP
 KC7b 
ovaries was the strongest, correlating with the stronger dorsalization 
observed in the phenotypic egg lay data.  Expression of GFP was minimally visible in 
dEGFR·GFP ovaries, suggesting that the dEGFR·GFP was targeted for Cbl degradation, 
while the human EGFR·GFP molecules may not have been degraded because the Cbl 
pathway is specific to Drosophila. 
A B C
D E
 
Figure 9: Chorion images from egg lays.  Chorions from flies misexpressing the noted transgene under the 
control of the CY2-GAL4 driver (A) wildtype W
1118
 , (B) EGFR, (C) dEGFR, (D) EGFR·GFP
KC7a
 , and 
(E)EGFR·GFP
KC7b 
flies were observed at 100x magnification using dark field microscopy.  The arrows indicate 
the appendage material on the chorions.  Dorsalization (the appearance of ectopic dorsal appendage material) of 
the chorion can be seen in Panels C through E, while Panels A & B appear normal with two thin appendages and 
little operculum material.   
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Optimization of Chemical Genetics Assay Conditions 
The ability of EGFR·GFP and dEGFR·GFP to induce dorsalization, provided an 
assay to examine the possibility of chemical genetics screens for the identification of 
TKIs.  In brief, flies misexpressing these transgenes lay dorsalized chorions but feeding 
these females an EGFR specific TKI would lead to reversion of the phenotype to 
wildtype.  To test this, flies were fed differing concentrations of either PD 168393 or CL-
387,783 over several days and chorion phenotypes were assessed.  In one trial, reversion 
of the chorion dorsalization was observed.  To optimize the assay, adjustments to the 
temperature, number of flies per well, well size, drug concentration, and other variables 
were performed over several trials (Table 1).  This preliminary reversion was unable to 
A B C 
 
Figure 10: Anti-EGFR ovarian staining. Antibody staining of A) EGFR·GFP
KC7a
, B) EGFR·GFP
 KC7b
, and 
C) EGFR using fluorescent microscopy at 100x magnification.  Note: The GFP tagged molecules showed 
much higher EGFR expression, suggesting a reason for the dorsalization phenotypes observed. 
A B C
 
Figure 11: GFP expression in the ovaries.  A) EGFR·GFP
KC7a
, B) EGFR·GFP
 KC7b
, and C) dEGFR·GFP were 
assessed for GFP expression using fluorescent microscopy at 100x magnification.  Expression of dEGFR·GFP 
was minimal, suggesting that it may have been targeted by Cbl degradation.  It was noted that, the human 
EGFR·GFP did not appear to be affected, showing GFP expression, suggesting that it was not subject to the same 
degradation. 
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be replicated.  Problems encountered with the assay included: the flies stopped laying 
eggs after 3 or 4 days, temperature fluctuations in the room affected the level of 
misexpression and phenotypes, and it was difficult to assess if flies were consuming TKI 
and how much. 
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DISCUSSION 
The identification of residues, surrounding C-tail tyrosines, conserved between 
Drosophila dEGFR and human ErbB highlighted the possibility of utilizing Drosophila 
for the identification of novel cancer therapeutics.  The conserved sequences appear to be 
binding sites for pathway adaptor molecules that activate intracellular pathways (e.g. 
MAPK).  With conserved tail sequences, sxLqRYsxDPT (conserved in EGFR, ErbB2, 
ErbB4 and dEGFR) and VxNPEYL (conserved in EGFR, ErbB2, ErbB4 and dEGFR) 
and adaptor molecules, it was likely that human ErbB receptors would to activate the fly 
MAPK pathway.  Confirming this, experimentally EGFR·GFP misexpression in 
Drosophila led to dorsalization of the chorions.  Since EGFR·GFP / CY2-GAL4 is 
properly expressed in the cells and active, I the human receptor must be capable of 
associating with Drosophila adaptor proteins necessary for activating the MAPK 
pathway. 
The reversion of dorsalized chorions to wildtype-looking chorions in one of the 
inhibitor trials indicates that the assay is feasible.  Unfortunately, positive results were 
only seen in one of seven trials, indicating that optimization is essential before libraries of 
chemical compounds can be screened.  Results from flies treated with known inhibitors 
must be able to produce suppress dorsalization in EGFR·GFP chorions at a frequency 
(estimated >30%) capable of being detected in a high throughput format.  Assay results 
from treatment with known EGFR inhibitors, such as PD 168393 and CL-387,785, must 
be consistent before the assay can become a practical tool for library screening.  Once the 
assay is optimized, I suggest it will be a useful tool for in vivo screening of compound 
libraries for the development of novel cancer therapeutics.  With work, the chemical 
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genetics assay can be developed into a high throughput (384 well plate) pharmaceutical 
screening method. 
 Additionally, the assay could be expanded to screen for inhibitors for other 
RTKs.  Since some RTK family members contained consensus sequences in their C-tail 
that matched the ErbB and dEGFR adaptor binding sites, it seems likely that other human 
RTKs expressed in Drosophila would activate the MAPK pathway and thus the chorion 
assay could be used to screen for additional receptor specific inhibitors.  For RTKs 
without the conserved adaptor binding site, its addition could potentially enable the same 
assay to be used. 
Together this work demonstrates this Drosophila assay has the potential to be a 
useful chemical genetics screening tool for TKIs and facilitate the development of novel 
therapeutics targeting a class of receptors implicated in a host of human diseases. 
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